Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature-Reference-Cited by-同舟云学术

Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature

Published:2015-07 Issue:7 Volume:39 Page:739-748
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Börschel Niklas^ORCID,Schwöppe Christian^ORCID,Zerbst Caroline,Angenendt Linus,Kessler Torsten,Klapper Wolfram,Giovannoni Leonardo,Elia Giuliano^ORCID,Neri Dario,Berdel Wolfgang E.,Mesters Rolf M.,Schliemann Christoph

Funder

Philogen

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference47 articles.

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma;Armitage;Blood,1997

2. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project;Sant;Blood,2010

3. Improvement of overall survival in advanced stage mantle cell lymphoma;Herrmann;J Clin Oncol,2009

4. Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)

5. Treatment of older patients with mantle-cell lymphoma;Kluin-Nelemans;New Engl J Med,2012

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune microenvironment of cervical cancer and the role of IL-2 in tumor promotion;Cytokine;2023-10

2. The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study;Leukemia & Lymphoma;2023-07-09

3. The application of Interleukin-2 family cytokines in tumor immunotherapy research;Frontiers in Immunology;2023-03-02

4. Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse;Blood Advances;2022-06-22

5. Engineering interferons and interleukins for cancer immunotherapy;Advanced Drug Delivery Reviews;2022-03